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A 40-year-old female visited our clinic for visual disturbance of the right eye, in which a few creamy-yellow retinal 
lesions and visual field constrictions were noted. She had been treated for primary CNS lymphoma and was in 
complete remission. After failure to follow-up for three months, she lost vision in the right eye, at which time active 
panuveitis was seen. Decreased vision and field constriction was observed in the left eye. Her left eye showed a 
granular pattern and dye leakage from the vessels and disc on fluorescein angiography and small RPE humps 
were seen in optical coherence tomography (OCT). Diffuse large malignant B-cells with strong immunoreactivities 
with CD20 immunostaining were seen in the epiretinal membrane biopsy specimen. Intravitreal injections of metho-
trexate (MTX) (800 μg/0.1 ml in the right eye, 400 μg/0.05 ml in the left eye) were performed twice weekly for one 
month, once weekly for the following month, once every two weeks for the next month, followed by nine monthly 
injections. Both eyes were free from malignant cells on vitreous biopsy six months later. There was no leakage 
seen by angiography, but the granular pattern persisted. Visual field constriction was slightly improved, and the 
small RPE humpsdetachments seen in OCT disappeared. EOG Arden ratio was decreased in both eyes, and b 
wave amplitude of scotopic ERG was decreased in the left eye. She was free from recurrence until six months 
later. No ocular complications except minimal opacity of the crystalline lenses were noted in both eyes.
Korean J Ophthalmol 2009;23:210-214 ⓒ 2009 by the Korean Ophthalmological Society.
Key Words: Intravitreal injection, Masquerade syndrome, Methotrexate, Primary intraocular lymphoma, Uveitis
Received: October 13, 2008    Accepted: August 7, 2009
Reprint requests to Youngwook Cho, MD. Department of Ophthalmology, 
Fatima Hospital, #576-31  Sinam-dong, Dong-gu, Daegu 701-600, Korea. Tel:
82-53-940-7143, Fax: 82-53-954-7417, E-mail: vitreo-retina@hanmail.net
* This study was presented as a poster at the 99th annual meeting of the 
Korean Ophthalmological Society in April, 2008.
Primary intraocular lymphoma (PIOL) is considered to be 
a subset of primary CNS lymphoma (PCNSL).
1 One-fifth of 
patients with PCNSL may demonstrate ocular involvement at 
the time of diagnosis, and the eye can be involved prior of the 
onset of CNS disease.
2,3 The exact incidence of PIOL is un-
known, but it is reported to be in the range of  30 to 50 cases per 
10 million people in the United States.
4,5 Only one case has been 
reported in Korea.
6
So far, there are three main treatment options for PIOL; sys-
temic high-dose MTX injection, orbital irradiation, and intra-
vitreal chemotherapy with MTX injections. These may be com-
bined or used separately.
7,8 Initial approaches for the treatment 
of  PIOL/PCNSL centered on radiotherapy, but it had a minimal 
effect on survival and may have been associated with radiation 
retinopathy.
9 Isolated radiation therapy is currently less com-
monly used,
10 and treatment can be limited to the eye in pa-
tients with PIOL limited to the eye.
11 There are some reports 
of PIOL effectively treated with intravitreal chemotherapy, and 
it has been often recommended as a first-line therapy for initial 
and recurrent PIOL.
11-13
To our knowledge, this is the first report of  PIOL treated by 
intravitreal chemotherapy, and the first to describe fluorescein 
angiographic findings, visual field exams, OCT findings and 
the electrophysiological characteristics of  PIOL in Koreas.
Case Report
A 40-year-old female visited our clinic for agradual visual 
disturbance in her right eye in January 2007. Her best-corrected 
visual acuity (BCVA) was 20/160 OD and 20/20 OS. A few 
barely detectable creamy-yellow retinal lesions were seen in 
the right eye. Eighteen months prior, she had been diagnosed 
with PCNSL in the right temporo-parietal lobe which had been 
pathologically confirmed as malignant large B-cells. Systemic 
chemotherapy with MTX was used initially, but it failed. Com-
plete remission was achieved by whole brain irradiation. A gra-
nular pattern of mixed hyperfluorescent and hypofluorescent 
spots, along with leakage from the retinal vessels and the optic 
disc, were observed in fluorescein angiography of the right eye. 
Her visual field was considerably constricted and OCT (STRA-
TUS OCT model 3000, Zeiss Instruments INC. San Leandro, 
CA) showed small irregular RPE detachments in the right eye 
(Fig. 1). P1 amplitude and latency of the right eye were mar-
kedly decreased compared with those of the left eye, as deter-E Kim, et al. A CASE OF PIOL TREATED BY INTRAVITREAL MTX
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Fig. 1. (A) Fluorescein angiography; some perivascular dye leakage, disc hyperfluorescence and granular patterns of scattered hypofluorescent 
and hyperfluorescent spots are seen in the right eye. (B) Visual field of the right eye; considerable peripheral constriction is seen in pattern 
deviation. (C) OCT of the right eye; small RPE humps are seen.
mined by pattern visual evoked potentials (VEP). Prominent 
suppression of the central signal was noted in multifocal ERG 
of the right eye compared with that of the left eye (Fig. 2).
After three months of failure to follow-up, the patient’s BCVA 
decreased to no light perception (NLP) OD and 20/200 OS, and 
active panuveitis was observed in the right eye. Shallow retinal 
detachment, vitreous debris and chorioretinal thickening were 
detected by ultrasonography. The left eye had mild uveitis and 
multiple vitreous seedings. It showed a granular pattern and 
leakage in angiography, small RPE humps in OCT, and con-
siderable visual field constriction (Fig. 3). A thorough systemic 
evaluation was performed, but there was no evidence of int-
racranial or visceral involvement, and the hematologic exam 
was nonspecific except for an elevated erythrocyte sedimen-
tation rate. Mega-dose intravenous steroid therapy was carried 
out, followed by diagnostic vitrectomy with retinal biopsy of 
the right eye. 
Diffuse large malignant B-cells with strong immunoreac-
tivities in CD20 immunostaining were seen in the preretinal 
membrane biopsy specimen otherwise, no abnormal cells were 
obtained from the vitreous biopsy (Fig. 4). Intravitreal injec-
tions of MTX (800 μg/0.1 ml in the right eye, 400 μg/0.05 ml 
in the left eye) were performed twice weekly for one month, 
once weekly for the next month, once every two weeks for the 
following month, followed by nine monthly injections. During 
the treatment, punctuate epithelial erosions and vortex kerato-
pathy developed, but they subsided completely with topical in-
stillation of 0.003% leucovorin eye drops and lubricants (Fig. 5).
The final BCVA was NLP OD, 20/20 OS, and both eyes were 
free from malignant cells in vitreous biopsy six months later. 
The granular pattern on fluorescein angiography was persistent 
but there was no dye leakage (Fig. 6). In the left eye, the visual 
field constriction was slightly improved, and the small RPE 
humps in OCT had disappeared. Although P1 latency was mar-
kedly delayed in the right eye compared with that of the left 
eye, the P1 amplitudes showed a minimal difference in flash 
VEP. The EOG Arden ratio was 0.9604 OD and 1.231 OS. The 
amplitude of b waves was markedly decreased in a scotopic 
ERG of the left eye the photopic ERG response, oscillatory po-
tentials and 30 Hz flicker response were relatively well preser-
ved, with ERG waves being flat in the right eye. The patient was 
free of intracranial and ocular recurrence until six months later. 
No ocular complications except minimal opacities of the crys-
talline lenses were noted in both eyes.Korean J Ophthalmol Vol.23, No.3, 2009
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Fig. 2. Multifocal ERG; trace arrays and 3D-topography ofthe response density in the right eye shows prominent suppression of the central sig-
nal compared with that of the left eye.
Discussion
Of ocular masquerade syndromes, PIOL is reported to be the 
most common.
14 PIOL typically presents as a posterior uveitis
4 
non-specific findings of vitreous debris, chorioretinal thicke-
ning, widening of the optic nerve, elevated chorioretinal lesions, 
and retinal detachment can be seen in ultrasonography.
15 Sub-
retinal and sub-RPE infiltrations of PIOL are reported to be 
common, and creamy-yellow lesions on a fundal exam might 
be associated with PED,
16 which was demonstrated in our 
OCT images. On fluorescein angiography, small sub-RPE in-
filtrations may appear as blocked hypofluorescence, and as 
the tumor regresses, it can become an RPE window defect.
16 
In our case, vasculitis and disc leakage disappeared as the tumor 
regressed; the granular pattern which might have been due to 
clumps of pigment epithelial cells, RPE atrophy and subretinal 
fibrosis, were persistent. Vitreous biopsy can be a useful tool to 
diagnose PIOL, but prior steroid therapy might suppress the 
number of vitreous cells, including lymphoma cells, which may 
result in a negative vitreous cytology.
17 
Electrophysiological findings obtained from eyes with PIOL 
were commented on in a brief report by Wang et al.
18 which 
showed subnormal rod and cone responses. In our case, the b 
wave amplitude of the scotopic ERG of the left eye was mar-
kedly decreased; other ERG waves might be subnormal but were 
relatively well preserved. The EOG Arden ratio was signifi-
cantly reduced in both eyes and could represent abnormal outer 
retinal and RPE functions. E Kim, et al. A CASE OF PIOL TREATED BY INTRAVITREAL MTX
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Fig. 3. Fluorescein angiography shows a granular pattern and leakage from vessels in the left eye.
AB
Fig. 4. (A) H-E stain of the preretinal membrane shows a diffuse infiltration of atypically large lymphoid cells (×400). (B) CD20 immunostain-
ing shows diffuse strong immunoreactivities in the tumor cells (×400).
OD OS
Fig. 5. Toxic epithelial keratopathy is seen in both eyes.Korean J Ophthalmol Vol.23, No.3, 2009
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Fig. 6. Fluorescein angiography shows a persistent granular pattern but no dye leakage.
Intravitreal chemotherapy has been reported to have few com-
plications,
11,12 and because MTX is well tolerated by intraocular 
tissues, repeated injections are feasible without retinal toxicity.
19 
Toxic keratopathy can also be easily managed with topical leu-
covorin eye drops and lubricants. 
We modified the chemotherapy protocol of a previous report
12 
by adding two additional once-every-two-week injections for 
consolidation because the patient had useful vision in only one 
eye and any other treatment choice was not readily available. 
We also used a double dose regimen in the right eye where 
tumor involvement of the vitreous and retina was massive, no 
useful vision remained, and, being a vitrectomized eye, a shorter 
half-life of MTX was expected. Intravitreal chemotherapy was 
effective even though the patient had a history of systemic che-
motherapy failure for PCNSL.
In summary, primary intravitreal chemotherapy can be effec-
tively used to treat PIOL and had minimal ocular complica-
tions in this patient.
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